Who Is Really in Charge of Drug Scheduling? DEA authority, HHS scientific review, and the legal fight over how U.S. controlled substance decisions are made

U.S. drug scheduling authority sits at the intersection of law, science, and executive power. Controlled substance decisions are shaped by the Drug Enforcement Administration and the Department of Health and Human Services, with recurring disputes over how much weight scientific and medical findings must carry in final scheduling outcomes. Federal scheduling affects whether substances are treated as having accepted medical use, abuse potential, and safety risks, which in turn determines research access, criminal penalties, prescribing limits, and regulatory oversight. Legal fights over who is really in charge often turn on statutory interpretation, administrative procedure, and the boundary between expert review and enforcement discretion. That question matters well beyond any single drug because scheduling frameworks influence pharmaceutical development, public health policy, and the pace of evidence-based reform. Shifts in agency authority can change how quickly emerging evidence is recognized and how resistant the system remains to rescheduling or descheduling efforts.